Advertisement

Transcriptome profiling reveals PDZ binding kinase as a novel biomarker in peritumoral brain zone of glioblastoma

  • Banavathy S. Kruthika
  • Ruchi Jain
  • A. Arivazhagan
  • R. D. Bharath
  • T. C. Yasha
  • Paturu Kondaiah
  • Vani Santosh
Laboratory Investigation

Abstract

Purpose

Peritumoural brain zone (PT) of glioblastoma (GBM) is the area where tumour recurrence is often observed. We aimed to identify differentially regulated genes between tumour core (TC) and PT to understand the underlying molecular characteristics of infiltrating tumour cells in PT.

Methods

17 each histologically characterised TC and PT tissues of GBM along with eight control tissues were subjected to cDNA Microarray. PT tissues contained 25–30% infiltrating tumour cells. Data was analysed using R Bioconductor software. Shortlisted genes were validated using qRT-PCR. Expression of one selected candidate gene, PDZ Binding Kinase (PBK) was correlated with patient survival, tumour recurrence and functionally characterized in vitro using gene knock-down approach.

Results

Unsupervised hierarchical clustering showed that TC and PT have distinct gene expression profiles compared to controls. Further, comparing TC with PT, we observed a significant overlap in gene expression profile in both, despite PT having fewer infiltrating tumour cells. qRT-PCR for 13 selected genes validated the microarray data. Expression of PBK was higher in PT as compared to TC and recurrent when compared to newly diagnosed GBM tumours. PBK knock-down showed a significant reduction in cell proliferation, migration and invasion with increase in sensitivity to radiation and Temozolomide treatment.

Conclusions

We show that several genes of TC are expressed even in PT contributing to the vulnerability of PT for tumour recurrence. PBK is identified as a novel gene up-regulated in PT of GBM with a strong role in conferring aggressiveness, including radio-chemoresistance, thus contributing to recurrence in GBM tumours.

Keywords

GBM Peritumoural brain zone Gene expression profile PBK Recurrence 

Notes

Acknowledgements

The results presented here are in part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov/. We acknowledge Prof. Kumarvel Somasundaram, Indian Institute of Science, for his support and guidance. We thank Prof. Subba Rao, Department of Microbiology and Cell Biology, Indian Institute of Science, for providing shPBK constructs as a kind gift. This work was carried out as a part of the project under the umbrella of Centre of Excellence in Neuro-Oncology funded by Department of Biotechnology, Government of India; University Grants Commission is acknowledged for fellowship to BSK. PK’s lab received core support from the IISc-DBT partnership program and DST-FIST infrastructure funding. All the project investigators and project assistants of DBT-COE are acknowledged. We acknowledge Mr. K. Manjunath, Department of Neuropathology for the preparation of figure montages.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The experiments conducted for this manuscript comply with current laws of the country.

Supplementary material

11060_2018_3051_MOESM1_ESM.tiff (5.6 mb)
Supplementary Figure 1 (TIFF 5782 KB)
11060_2018_3051_MOESM2_ESM.tif (14.1 mb)
Supplementary Figure 2 (TIF 14390 KB)
11060_2018_3051_MOESM3_ESM.docx (23 kb)
Supplementary File 1 (DOCX 22 KB)
11060_2018_3051_MOESM4_ESM.docx (13 kb)
Supplementary File 2 (DOCX 13 KB)
11060_2018_3051_MOESM5_ESM.xlsx (17 kb)
Supplementary Table 1 (XLSX 16 KB)
11060_2018_3051_MOESM6_ESM.xlsx (482 kb)
Supplementary Table 2 (XLSX 481 KB)
11060_2018_3051_MOESM7_ESM.xlsx (10 kb)
Supplementary Table 3 (XLSX 10 KB)

References

  1. 1.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820.  https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMedGoogle Scholar
  2. 2.
    Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Cancer/Radiothér 9:196–197.  https://doi.org/10.1016/j.canrad.2005.05.001 CrossRefGoogle Scholar
  3. 3.
    De Bonis P, Maira G, Balducci M, Sica G, Lauriola L (2008) Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113:841–846.  https://doi.org/10.1002/cncr.23624 CrossRefPubMedGoogle Scholar
  4. 4.
    Van Meter T, Dumur C, Hafez N, Garrett C, Fillmore H, Broaddus WC (2006) Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15(4):195–205.  https://doi.org/10.1097/01.pdm.0000213464.06387.36 CrossRefPubMedGoogle Scholar
  5. 5.
    Gill BJ, Pisapia DJ, Malone HR et al (2014) MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci.  https://doi.org/10.1073/pnas.1405839111 Google Scholar
  6. 6.
    Ruiz-Ontañon P, Orgaz JL, Aldaz B et al (2013) Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells 31(6):1075–1085.  https://doi.org/10.1002/stem.1349 CrossRefPubMedGoogle Scholar
  7. 7.
    Mangiola A, Saulnier N, De Bonis P et al (2013) Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study. PLoS ONE.  https://doi.org/10.1371/journal.pone.0057145 Google Scholar
  8. 8.
    Tamura R, Ohara K, Sasaki H, Morimoto Y, Yoshida K, Toda M (2018) Histopathological vascular investigation of the peritumoral brain zone of glioblastomas. J Neurooncol 136(2):233–241.  https://doi.org/10.1007/s11060-017-2648-9 CrossRefPubMedGoogle Scholar
  9. 9.
    Wagner KW, Sapinoso LM, El-rifai W et al (2004) Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene.  https://doi.org/10.1038/sj.onc.1207861 Google Scholar
  10. 10.
    Iyer J, Moghe S, Furukawa M, Tsai M (2011) What’ s Nu (SAP) in mitosis and cancer ? Cell Signal 23(6):991–998.  https://doi.org/10.1016/j.cellsig.2010.11.006 CrossRefPubMedGoogle Scholar
  11. 11.
    Han S, Li Z, Master LM, Master ZW, Wu A (2014) Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin b 1-ERK pathway. Br J Cancer.  https://doi.org/10.1038/bjc.2014.435 Google Scholar
  12. 12.
    Joel M, Mughal AA, Grieg Z et al (2015) Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Mol Cancer 14:121.  https://doi.org/10.1186/s12943-015-0398-x CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hoelzinger DB, Mariani L, Weis J et al (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7(1):7–16.  https://doi.org/10.1593/neo.04535 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang M, Ye G, Li J, Wang Y (2015) Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy. Brain Tumor Pathol 32(4):229–236.  https://doi.org/10.1007/s10014-015-0233-5 CrossRefPubMedGoogle Scholar
  15. 15.
    Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis 1. Neuro-oncology.  https://doi.org/10.1215/S1152851704001115 PubMedPubMedCentralGoogle Scholar
  16. 16.
    Lin B, Lee H, Yoon J et al (2015) Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene. Oncotarget.  https://doi.org/10.18632/oncotarget.3030 Google Scholar
  17. 17.
    Ma Z, Song J, Liu S et al (2016) Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation. Oncol Lett 12:4021–4026.  https://doi.org/10.3892/ol.2016.5147 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Baykara O, Tansarikaya M, Bulut P, Demirkaya A, Buyru N (2017) CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC). Gene 618:65–68.  https://doi.org/10.1016/j.gene.2017.04.010 CrossRefPubMedGoogle Scholar
  19. 19.
    Du Z, Li L, Huang X, Jin J, Huang S, Zhang Q et al (2016) The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget.  https://doi.org/10.18632/oncotarget.7822 Google Scholar
  20. 20.
    Wang D, Sun S-Q, Yu Y-H, Wu W-Z, Yang S-L, Tan J-M (2014) Suppression of SCIN inhibits human prostate cancer cell proliferation and induces G0/G1 phase arrest. Int J Oncol 44(1):161–166.  https://doi.org/10.3892/ijo.2013.2170 CrossRefPubMedGoogle Scholar
  21. 21.
    Chen XM, Guo JM, Chen P et al (2014) Suppression of scinderin modulates epithelial mesenchymal transition markers in highly metastatic gastric cancer cell line SGC 7901. Mol Med Rep 10(5):2327–2333.  https://doi.org/10.3892/mmr.2014.2523 CrossRefPubMedGoogle Scholar
  22. 22.
    Schäfer A, Teufel J, Ringel F et al (2012) Aldehyde dehydrogenase 1A1-a new mediator of resistance to temozolomide in glioblastoma. Neuro Oncol 14(12):1452–1464.  https://doi.org/10.1093/neuonc/nos270 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Popescu ID, Codrici E, Albulescu L et al (2014) Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches. Proteom Sci 12(1):1–14.  https://doi.org/10.1186/s12953-014-0047-0 CrossRefGoogle Scholar
  24. 24.
    Pen A, Moreno MJ, Durocher Y, Deb-Rinker P, Stanimirovic DB (2008) Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-β signaling. Oncogene 27(54):6834–6844.  https://doi.org/10.1038/onc.2008.287 CrossRefPubMedGoogle Scholar
  25. 25.
    Guo KT, Fu P, Juerchott K et al (2014) The expression of Wnt-inhibitor DKK1 (Dickkopf 1) is determined by intercellular crosstalk and hypoxia in human malignant gliomas. J Cancer Res Clin Oncol 140(8):1261–1270.  https://doi.org/10.1007/s00432-014-1642-2 CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao S-C, Zhou B-W, Luo F, Mao X, Lu Y-J (2015) The structure and function of NKAIN2-a candidate tumor suppressor. Int J Clin Exp Med 8(10):17072–17079PubMedPubMedCentralGoogle Scholar
  27. 27.
    Shukla S, Patric IRP, Patil V et al (2014) Methylation silencing of ULK2, an autophagy gene, is essential for astrocyte transformation and tumor growth. J Biol Chem 289(32):22306–22318.  https://doi.org/10.1074/jbc.M114.567032 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Drucker KL, Paulsen AR, Giannini C et al (2013) Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro Oncol 15(3):305–318.  https://doi.org/10.1093/neuonc/nos313 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ (2012) Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol 38(2):201–212.  https://doi.org/10.1111/j.1365-2990.2011.01207.x CrossRefPubMedGoogle Scholar
  30. 30.
    Chen M, O’Connor KL (2005) Integrin α6β4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 24(32):5125–5130.  https://doi.org/10.1038/sj.onc.1208729 CrossRefPubMedGoogle Scholar
  31. 31.
    Win KT, Lee S-W, Huang H-Y et al (2013) Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma. Tumour Biol 34(6):3923–3931.  https://doi.org/10.1007/s13277-013-0980-z CrossRefPubMedGoogle Scholar
  32. 32.
    Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F (2010) Galectins and gliomas. Brain Pathol 20(1):17–27.  https://doi.org/10.1111/j.1750-3639.2009.00270.x CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Shwetha SD, Shastry AH, Arivazhagan A (2016) Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma. Pathol Res Pract 212(1):17–23.  https://doi.org/10.1016/j.prp.2015.11.002 CrossRefPubMedGoogle Scholar
  34. 34.
    Pajares MJ, Agorreta J, Salvo E, Behrens C, Wistuba II, Montuenga LM et al (2014) TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients. Br J Cancer 110(6):1545–1551.  https://doi.org/10.1038/bjc.2014.33 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Zhu J, Chen X, Liao Z, He C, Hu X (2015) TGFBI protein high expression predicts poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol 8(1):702–710PubMedPubMedCentralGoogle Scholar
  36. 36.
    Gales D, Clark C, Manne U, Samuel T (2013) The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol.  https://doi.org/10.1155/2013/859154 PubMedPubMedCentralGoogle Scholar
  37. 37.
    Abe Y, Matsumoto S, Kito K, Ueda N (2000) Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 275(28):21525–21531.  https://doi.org/10.1074/jbc.M909629199 CrossRefPubMedGoogle Scholar
  38. 38.
    Brown-clay JD, Shenoy DN, Timofeeva O, Bhaskar V, Nandi AK, Banerjee PP (2015) PBK/TOPK enhances aggressive phenotype in prostate cancer via β-Catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget 6(17):15594–15609.  https://doi.org/10.18632/oncotarget.3709 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Park J, Lin M, Nishidate T, Nakamura Y, Katagiri T (2006) PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res.  https://doi.org/10.1158/0008-5472.CAN-06-1601 PubMedCentralGoogle Scholar
  40. 40.
    Shih M, Chen J, Wu Y, Jan Y, Yang B, Lu P, Lai J (2012) TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 31:2389.  https://doi.org/10.1038/onc.2011.419 CrossRefPubMedGoogle Scholar
  41. 41.
    Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Langmoen IA et al (2015) Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. Oncotarget 6(28):26192–26215.  https://doi.org/10.18632/oncotarget.4613 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Luo Q, Lei B, Liu S, Chen Y, Sheng W, Lin P et al (2014) Expression of PBK/TOPK in cervical cancer and cervical intraepithelial neoplasia. Int J Clin Exp Med 7(11):8059–8064Google Scholar
  43. 43.
    Hayashi T, Hayakawa Y, Koh M, Tomita T, Nagai S, Kashiwazaki D, Kuroda S et al (2018) Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma. Neuropathology 38(2):144–153.  https://doi.org/10.1111/neup.12446 CrossRefPubMedGoogle Scholar
  44. 44.
    Quan C, Xiao J, Duan Q, Yuan P, Xue P, Dogan S, Liu L et al (2018) T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma. Oncotarget 9(8), 7782–7795.  https://doi.org/10.18632/oncotarget.23674 CrossRefPubMedGoogle Scholar
  45. 45.
    Dou X, Wei J, Sun A, Shao G, Childress C, Yang W, Lin Q (2015) PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation. Cancer Cell Int 15(1):1–9.  https://doi.org/10.1186/s12935-015-0178-0 CrossRefGoogle Scholar
  46. 46.
    Lee HC, Her N-G, Kang D, Jung SH, Shin J, Lee M, Lee J-S, et al (2017) Radiation-inducible miR-770-5p sensitizes tumors to radiation through direct targeting of PDZ-binding kinase. Cell Death Dis 8(3):e2693.  https://doi.org/10.1038/cddis.2017.116 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Sugimori M, Hayakawa Y, Koh M, Hayashi T, Tamura R, Kuroda S (2018) Targeting the T-Lak cell originated protein kinase by OTS964 shrinks the size of power-law coded heterogeneous glioma stem cell populations. Oncotarget 9(3):3043–3059.  https://doi.org/10.18632/oncotarget.23077 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeuropathologyNational Institute of Mental Health and NeuroscienceBangaloreIndia
  2. 2.Department of NeurosurgeryNational Institute of Mental Health and NeuroscienceBangaloreIndia
  3. 3.Department of Neuroimaging and Interventional RadiologyNational Institute of Mental Health and NeuroscienceBangaloreIndia
  4. 4.Department of Molecular Reproduction, Development and GeneticsIndian Institute of ScienceBangaloreIndia

Personalised recommendations